Shots:

• The P-III MONALEESA-3 study involves assessing of Kisqali (ribociclib) + fulvestrant in postmenopausal women with HR+/HER2- advanced or m-breast cancer
• The second phase of P-III MONALEESA-3 study resulted in meeting its 2EPs of OS with no new observed safety signals and consistent AEs with the previous P-III study results. These results follow MONALEESA-7 study results which demonstrated improved OS in patients with HR+/HER2- advanced breast cancer in pre/peri-menopausal women
• Kisqali is the CDK4/6 inhibitor- being evaluated in P-III NATALEE study with endocrine therapy in the adjuvant treatment of HR+/HER2- early breast cancer and has received FDA & EMA’s approval in Mar’2017 and Aug’2017 respectively

Click here to­ read full press release/ article | Ref: Novartis | Image: Twitter